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psRゲザゲズCs	 Quantifiab旭e	 mu旭timer	 resu旭ts	 were	 avai旭ab旭e	 within	 one	 working	 days	
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ゲ科 |科INTRODUCTION
Von	Wi旭旭ebrand	disease	ｪVWDｫ	is	a	hemorrhagic	disorder	that	is	caused	



















method	 standardizationp	 旭ength	 of	 testp	 requirement	 of	 specia旭ist	
equipmentp	and	often	variab旭e	and	subjective	resu旭tss	In､	house	VWF	
mu旭timers	 ｪIHVWMｫ	may	be	performed	using	 sodium	dodecy旭	 su旭､
phate	ｪSDSｫ	agarose	ge旭	e旭ectrophoresisp	often	fo旭旭owed	by	Western	
b旭ottingp	 then	 visua旭ization	 by	 methods	 inc旭uding	 via	 radioactive	
Iodine	ｪIゲゴズｫ	autoradiographyp	chemi旭uminescencep7	infrared	f旭uores､




















and	 Thrombosis	 Centrep	 UKq	 and	 site	 ゴp	 Centrum	 f訟r	





























or	historica旭	diagnosis	of	 type	ゴB	VWD	by	 旭ow､	dose	RIPA12	 ｪsee	






A	 cohort	 of	 these	 patients	 was	 a旭so	 tested	 fo旭旭owing	 admin､
istration	 of	 Octim	 ｪDesmopressinp	 Ferringp	 Parsippanyp	 NJp	 USAｫp	
Wi旭fact	 ｪLFBp	 Courtaboeufp	 Franceｫp	 Wi旭ate	 ｪOctapharmap	 Lachenp	
Switzer旭andｫp	Haemate	P	or	Voncentro	 ｪboth	CSL	Behringp	King	of	
Prussiap	PAp	USAｫs
Samp旭es	 from	 four	 patients	 with	 thrombotic	 thrombo､
cytopenic	 purpura	 ｪTTPｫ	 and	 reduced	 ADAMTSゲザ	 activity	





Cou旭terp	 Vi旭旭epintep	 Franceｫ	 with	 旭eve旭s	 ranging	 from	 ゲグググ	 to	
芦ゼズグ	IU｠mL	 ｪreference	 interva旭	┑ゴグ	IU｠mLｫ	 and	by	 immunoturbidi､
metry	ｪRandoxp	Crum旭inp	UKｫ	with	旭eve旭s	ranging	from	ゾザゴ	to	ジ芦ザジ	
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At	 site	 ゲp	 VWF	 assays	were	 performed	 by	 Siemens	 VWF	 antigen	
and	Innovance	VWF	Ac	ｪMarburgp	Germanyｫp	a	GPゲbM	VWF	activ､
ity assay.2	 A旭旭	 assays	were	 performed	 on	 Sysmex	 CSズゲググi	 instru､
mentation	 ｪKobep	 Japanｫs	 VWFrCB	was	 performed	 by	 ELISA	 using	
Technozym	CBA	ｪTechnoc旭onep	Viennap	Austriaｫs
At	 site	 ゴp	 VWF	 assays	 were	 performed	 by	 VWF	 Ac	 or	
VWFrRCop	 and	 VWFrAg	 using	 ACL	 TOPゼズグCT	 instrumenta､
tion	 ｪa旭旭	Werfenp	Barce旭onap	 Spainｫs	VWFrCB	was	performed	by	
Euroana旭yser	 one	 ｪEuro	Diagnostic	 Systemsp	 Tami旭	Nadup	 Indiaｫ	




phoresisp	 a	modification	 of	 two	methods	 by	 omission	 of	 acry旭a､
mide.ゲジpゲズ	This	was	routine旭y	performed	at	ゲs葦鯵	agarose	ｪSeaKem	
HGT	ｬPｭ	agaroseq	Lonza	Bio旭ogica旭sp	S旭oughp	UKｫ	but	ゲsグ鯵	agarose	
was	 a旭so	 used	 in	 patients	 that	 demonstrated	 a	 旭oss	 of	 HMWMs	




human	VWF	po旭yc旭ona旭	 antibody	 and	 swine	 anti､	rabbit	 antibody	






HMWMs	Mu旭timer	 patterns	were	 either	 considered	 qua旭itative旭y	
norma旭p	reduction	of	HWMp	gross	reduction	of	HWM	ｪand	IMWMｫp	





Hydrasys	 ゴ	 Scan	 instrumentation	 to	 perform	 agarose	 ge旭	 e旭ectro､
phoresis	using	preformed	ゴ鯵	agarose	ge旭sp	 direct	 immunofixationp	
visua旭ization	with	 peroxidase､	旭abe旭旭ed	 antibodyp	 and	 densitometrys	
HズVWM	Kits	were	provided	by	Sebia	for	 this	eva旭uations	Samp旭es	
were	initia旭旭y	tested	at	a	ゲr葦	di旭ution	of	p旭asma	with	samp旭e	di旭uents	
During	 this	 studyp	 individua旭s	with	VWFrAg	 旭eve旭s	 be旭ow	ゴグ	IU｠dL	
or	greater	than	ゲズグ	IU｠dL	were	a旭so	tested	at	ゲrジ	or	ゲrゲゴ	di旭utions	
of	 p旭asmap	 respective旭yp	 according	 to	 the	 manufacturervs	 recom､
mendations	at	the	commencement	of	the	studys	The	manufacturer	
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has	 since	 revised	 the	methodo旭ogy	 to	 di旭ute	 samp旭es	 greater	 than	
ゲズグ	IU｠dL	 at	 ゲrゲグs	 Densitometry	 was	 performed	 by	 Hydrasys	 ゴ	
Scans	 The	 percentage	 of	 LMWMp	 IMWMp	 and	 HMWM	 were	 as､
sessed	using	Phoresis	software	ｪSebiaｫ	with	peaks	ゲ､	ザ	designated	as	
LMWMp	peaks	ジ､	ゼ	as	IMWMp	and	peaks	┒ゼ	as	HMWM	according	to	
the	manufacturervs	 recommendationss	 A	 norma旭	 旭eve旭	 qua旭ity	 con､
tro旭	ｪQCｫ	p旭asmap	Chrono旭og	VWF	reference	p旭asma	ｪHavertownp	PAp	
USAｫ	was	inc旭uded	on	each	ge旭s
Lower	 旭imit	 of	 detection	 for	 the	 densitometry	 was	 eva旭uated	
using	SSC	旭ot	ジ	p旭asma	ｪNIBSCp	Potters	Barp	UKｫ	di旭uted	to	ゴグp	ゲズp	ゲグp	
and	ズ	IU｠dL	in	FVIII	and	VWF	deficient	p旭asma	ｪWerfenｫs
Historica旭	 mutation	 ana旭ysis	 in	 Sheffie旭d	 and	 for	 those	 sam､




recent旭yp	 next	 generation	 sequencing	 was	 introduced	 and	 the	
entire	 coding	 region	 of	VWF	 ana旭yzed	 simu旭taneous旭ys	 The	 gene	
pane旭	 comprises	 ゲザ	 genes	 ana旭yzed	 using	 I旭旭umina	 HiSeq	 ゴズググ	
with	SureSe旭ectp	fo旭旭owed	by	bioinformatic	ana旭ysis	to	identify	se､
quence	to	identify	sequence	variantss
Mutation	 ana旭ysis	 was	 avai旭ab旭e	 for	 葦葦	 patients	 at	 site	 ゲ	 on旭y	








Inter､	assay	 coefficient	 of	 variation	 ｪCVｫp	 ca旭cu旭ated	 using	 the	




for	 IMWM	 ｪmean	ジゴs芦鯵p	 SD	ゲsズ葦ｫp	 and	葦sグ鯵	 for	HMWM	 ｪmean	
ザゼsズ鯵p	SD	ゴsゴ葦ｫs








dLs	 At	 decreasing	 VWFrAgp	 an	 increase	 to	 LMWM	was	 observed	
ｪゲズs芦鯵､	ザグs芦鯵	at	ゴグ	and	ズ	IU｠dLp	 respective旭yｫ	with	 旭oss	of	 IMWM	
ｪザ芦鯵､	ゴザsジ鯵ｫ	 but	 旭itt旭e	 change	 to	 HMWM	 ｪジ葦sゴ鯵､	ジズs芦鯵ｫs	 Be旭ow	
ゲグ	IU｠dLp	 a	 旭oss	 of	 definition	 to	 the	 densitometry	 peaks	 was	 ob､
served	ｪsee	Figure	ゲA､	Dｫs
Figure	ゴ	 presents	 the	 resu旭ts	 of	 the	 patient	 cohort	 exc旭uding	
those	with	 type	ゴNp	ザp	 and	AVWS	 for	 ease	of	 interpretations	The	








ザズ鯵	 in	 three	 further	 patientss	 Pズ	 and	 Pゲグp	 with	 HMWM	 ザザs葦鯵	





of	 ズゼ	 individua旭s	 had	 a	 qua旭itative旭y	 norma旭	 mu旭timer	 pattern	
with	both	methodss	Two	unre旭ated	patients	ｪPゴグズ	and	Pゴゲザｫ	had	
a	 旭oss	 of	HMWM	mu旭timers	with	 both	methodss	HMWM	were	





of	 IHVWM	 but	 norma旭	 HズVWM	 ｪHMWM	 ザ葦sゾ鯵ｫ	 ｪsee	 Figure	ザC	
and	Tab旭e	ゴｫ	and	was	found	to	be	compound	heterozygous	for	type	
ゴA	 and	 type	 ゴB	 VWD	 with	 psPゲゴ葦葦E	 and	 psPheゲズグゲSer	 amino	
acid	 substitutions	 in	 exon	 ゴ芦s	 Two	 re旭ated	 patients	 ｪP葦ジ	 and	 葦ズｫ	
with	a	psCゲゲザグF	change	 in	exon	ゴ葦p	had	visua旭旭y	norma旭	 IHVWMp	
but	HズVWM	observed	an	increase	in	LMWM	ｪジゾsザ	and	ザ葦sジ鯵ｫ	and	
decrease	 in	HMWM	 ｪゴズsザ	 and	 ザゴsゼ鯵ｫ	 ｪsee	 Tab旭e	ゴｫs	 VWFrAg	was	
ゴグ	IU｠dL	in	both	patientss
Ten	patients	had	psRゲゴグズH	amino	acid	change	ｪVicenza	VWDｫp	
VWF	 Ac｠VWFrAg	 ratios	 greater	 than	 グs葦	 and	 qua旭itative旭y	 nor､
ma旭	 IHVWMs	 VWFrAg	 was	 旭ess	 than	 ゲズ	IU｠dL	 in	 eight	 patientss	
Densitometry	 of	 HズVWM	 demonstrated	 that	 a旭旭	 had	 norma旭	
HMWM	but	six	patients	had	an	increase	in	the	旭owest	LMWMp	peak	
ゲ	ｪゴザs葦鯵､	ジゾsゲ鯵ｫs








visib旭e	 by	 IHVWM	whi旭st	 HズVWM	HMWM	 ranged	 from	 葦sズ鯵	 to	
ザゴsズ鯵s
















was	 homozygous	 for	 psQゲグズザHs	 An	 absence	 of	 a旭旭	mu旭timers	was	
observed	by	both	methods	 in	 type	ザ	VWDs	 It	was	not	possib旭e	 to	
perform	densitometry	in	this	groups
The	 mu旭timers	 of	 ゲ芦	 patientsp	 at	 旭east	 one	 patient	 from	 each	
type	of	VWDp	were	eva旭uated	prior	to	and	fo旭旭owing	treatment	with	
Desmopressin	 ｪn	┎	ゾｫ	 or	Haemate	P	 ｪn	┎	ゾｫs	 The	mean	densitometry	
pre	Desmopressin	was	 LMWM	ゲ葦s芦鯵p	 IMWM	ゴ葦sザ鯵p	 and	HMWM	
ズ葦sゾ鯵s	 Post､	Desmopressin	 means	 were	 ゲ葦sゾ鯵p	 ゴゼsゴ鯵p	 and	 ズズsゾ鯵p	
respective旭yp	with	an	 increase	above	 the	 top	of	 the	 reference	 range	





ゲ	VWDｫ	had	norma旭	HMWM	fo旭旭owing	 treatments	Paired	 t test ob､
served	no	statistica旭旭y	 significant	difference	 ｪP ┒ グsグズｫ	between	pre､	
and	post､	Haemate	P	for	LMWMp	converse旭yp	a	statistica旭旭y	significant	
difference	 was	 observed	 for	 both	 IMWM	 ｪP ┎ グsググゴｫ	 and	 HMWM	
ｪP ┎ グsグゲ葦ｫs	Three	type	ゴA	VWD	patients	were	treated	with	Wi旭fact	
and	 one	 type	 ザ	 VWD	 patient	 with	 Voncentros	 Post､	concentrate	
IHVWM	 were	 visua旭旭y	 norma旭	 in	 two	 of	 fourp	 howeverp	 HズVWM	
demonstrated	a	旭oss	of	HMWM	ranging	from	ゾsザ鯵	to	ゴグsゾ鯵	in	a旭旭	four	
individuals.















































































葦科 |科 科架 BOWYER ET AL.
that	had	a	 旭oss	of	HWMW	by	both	methods	had	norma旭	VWF	Ac｠
VWFrAg	ratios	of	グs葦ジ､	グsゼ葦s




observed	 in	 eight	 patients	 with	 e旭evated	 rheumatoid	 factor	 and	
three	patients	whose	b旭ood	was	drawn	in	citrate	or	EDTAs
ジ科 |科DISCUSSION
Overa旭旭	 agreement	 of	 ゾゲsゲ鯵	 was	 observed	 between	 methods	 in	
patients	with	norma旭	VWF	or	different	types	of	VWDs	Where	dis､











The	 rec旭assification	 of	 type	 ゴ	 VWD	 into	 four	 subgroups	 in	
ゲゾゾジ	 has	 旭ed	 to	 many	 conf旭icting	 reports	 旭inked	 to	 particu旭ar	
mutations	 in	 VWFsズ	 Severa旭	 mutations	 present	 in	 our	 cohortp	
inc旭uding	 psCゲゲザグFp	 psRゲゴグズHp	 psRゲザゲズCp	 and	 psRゲザゼジC｠Hp	
have	 been	 旭inked	 to	 more	 than	 one	 type	 or	 subtype	 of	 VWD	
in	 the	 旭iteratures	Patients	with	psCゲゲザグF	have	previous旭y	been	
c旭assified	 as	 both	 type	ゴAｪIIEｫ17	 and	 type	ゲ	VWD18 with some 
authors	 reporting	 an	 aberrant	 IHVWM	 patternpゲゼpゲゾ	 howeverp	
we	 observed	 a	 norma旭	mu旭timer	 pattern	 by	 IHVWM	 and	 a	 re､
duction	of	HMWM	with	HズVWM	in	three	patientss	Ten	patients	
with	psRゲゴグズH	 ｪVicenza	VWDｫ	were	c旭assified	as	 type	ゲ	VWD	
in	 this	 study	 a旭though	 this	 mutation	 has	 a旭so	 been	 c旭assified	
as	 type	 ゴM	 VWDs20	 Three	 patients	 with	 psRゲザゲズC	were	 c旭as､
sified	 as	 type	 ゴM	 but	 this	mutation	 has	 a旭so	 been	 旭inked	with	
type	ゴA	VWDsゲゾpゴゲpゴゴ	E旭even	individua旭sp	from	four	fami旭iesp	had	
psRゲザゼジC｠Hp	associated	with	both	type	ゴAゲゾ	and	ゴM23	VWDs	Of	
the	 seven	 re旭ated	 patientsp	 four	were	 grouped	 as	 type	ゴA	 and	
three	as	type	ゴMs	This	present	study	confirms	that	the	presence	
of	 a	 particu旭ar	 genetic	 variant	 does	 not	 a旭ways	 corre旭ate	 with	
phenotypic	 assayss	Additiona旭	 studies	 are	 required	 to	 compare	





trates	used	 in	 this	studyp	on旭y	a	sing旭e	 type	ゲ	VWD	patientp	had	
HMWM	 within	 norma旭	 旭imitss	 Not	 a旭旭	 high	 purity	 human	 VWF	
concentrates	 fu旭旭y	 restore	 HMWM	 to	 norma旭	 旭eve旭sp10	 a旭though	
Haemate	P	has	previous旭y	been	demonstrated	to	produce	a	signif､
icant	increase	to	HMWMpゴジ this was not observed in our cohort. 
Further	studies	are	needed	to	investigate	post	treatment	samp旭es	
using	HズVWMs
AVWS	 is	 caused	 by	 a	 number	 of	 mechanisms	 as	 reviewed	 by	
Mohrisゴズ	There	was	no	c旭ear	re旭ationship	between	VWF	Ac｠VWFrAg	
ratio	 and	 mu旭timer	 profi旭e	 in	 our	 patients	 howeverp	 agreement	
TABLE  ゲ科Mean	ｪand	rangeｫ	of	VWF	parameters	and	HズVWM	densitometry	of	patient	cohorts	inc旭uded	in	this	study
Groupp n
VWF Parameters Hydrasys 5 densitometry
VWFrAg ｪIU｠dLｫ VWF Ac ｪIU｠dLｫ Ratio VWF Act｠Ag LMWM ｪ鯵ｫ IMWM ｪ鯵ｫ HMWM ｪ鯵ｫ
Normal 
donorsp	ズゲ
ゲグゴ	ｪゼザ､	ゲズゼｫ ゾジ	ｪズ芦､	ゲ葦ゼｫ グsゾゴ	ｪグs葦ジ､	ゲsゴゾｫ ゲゼsザ	ｪゲグs芦､	ゴズsゾｫ ザザsグ	ｪゴザs芦､	ジザsジｫ ジゾsゾ	ｪザジsゼ､	ズゾsザｫ
Norma旭	VWFp	
ゼジ
ゾゾsズ	ｪズゴ､	ザグズｫ 芦ゾs芦	ｪズゴ､	ゴゼゼｫ グsゾザ	ｪグsゼグ､	ゲsゴ芦ｫ ゲゼsゲ	ｪゾsゲ､	ザゾsズｫ ザグsザ	ｪゴゲsゼ､	ザゾs葦ｫ ズゴsゴ	ｪゴゲsゾ､	葦ゼs芦ｫ
Type	ゲ	VWDp	
ジゼ
ザゼsゼ	ｪゲゴ､	葦葦ｫ ザザsゴ	ｪ芦､	ズ芦aｫ グs芦芦	ｪグs葦ズ､	ゲsザゴｫ ゴグsズ	ｪ芦sジ､	ジゾsザｫ ゴ芦	ｪゲ葦sゴ､	ジゲsジｫ ズゲs葦	ｪゴグsゴ､	ゼグsゾｫ
Type	ゲ	
Vicenzap	ゲグ
ゲグsゴ	ｪ葦､	ゴゲｫ ゾsザ	ｪズ､	ゲ芦ｫ グsゾ葦	ｪグs葦ゼ､	ゲsジザｫ ザザs葦	ｪゴゲsザ､	ジゾsゲｫ ゲズsゴ	ｪズ､	ザ芦s葦ｫ ズゲsゴ	ｪザゼs芦､	葦ザsゲｫ
Type	ゴAp	ザザ ジグsゴ	ｪゲザ､	ゲザゴｫ ゲザsゲ	ｪゲ､	ジジｫ グsザジ	ｪグsグジ､	グs葦グｫ 葦グsゼ	ｪゴ葦sゼ､	ゾグs葦ｫ ゴゲsゼ	ｪザsズ､	ジグsグｫ ゲゼs葦	ｪゲsゲ､	ジグsザｫ
Type	ゴBp	ゲ葦 ジザs芦	ｪゲゾ､	芦グｫ ゲジs葦	ｪ葦､	ザゲｫ グsザジ	ｪグsゴズ､	グs葦グｫ ズズsジ	ｪゴジsズ､	葦葦sゾｫ ザジsズ	ｪゴザ､	ジズsゴｫ ゲグsゴ	ｪザsゲ､	ザゴsズｫ
Type	ゴMp	ゴ芦 ザズsズ	ｪゾ､	ゾゾｫ ゲザsジ	ｪジ､	ゴゾｫ グsザゾ	ｪグsゲ葦､	グs葦グｫ ザゴs芦	ｪゾs芦､	葦ゼsゼｫ ゴザsジ	ｪズsズ､	ザ葦s葦ｫ ジザsゾ	ｪゴグsゴ､	ゼゲsジｫ
Type	ゴNp	ゲゲ 葦芦	ｪザジ､	ゲザ芦ｫ 83b	ｪザザ､	ゲ芦ゼｫ 1.1b	ｪグsゾ､	ゲsジｫ ゴゲsジ	ｪゲジsジ､	ザグsジｫ ザグs芦	ｪ葦sゴ､	ジグsゲｫ ジゼsゾ	ｪザゲsゼ､	葦ジsゾｫ
Type	ザp	ザ ┑ズ ┑ジ  No	peaks












howeverp	 four	 donorsp	 one	 fema旭e	 and	 three	 ma旭esp	 had	 LMWM	
ｪゴ芦sズ鯵､	ザザsズ鯵ｫ	which	 exceeded	 the	upper	 quarti旭e	 ┊ゲsズ	 IQR	va旭ue	
of	 ゴ葦sゴ鯵s	 These	 donors	 were	 considered	 statistica旭	 out旭iers	 and	














assay2	 that	uti旭izes	 two	gain	of	 function	mutations	 to	g旭ycopro､
tein	ゲb	ｪGPゲbｫ	 in	p旭ace	of	Ristocetin	and	p旭ate旭etss	The	VWFrAg	
and	 VWF	 Ac	 of	 mu旭timer	 discrepant	 patients	 were	 confirmed	
on	 repeats	 It	 is	 possib旭e	 that	 the	VWF	Ac	 assay	was	 旭ess	 sensi､
tive	 to	 certain	mutations	 than	 a	 traditiona旭	 VWFrRCos	 A	 previ､
ous	study	 reported	some	s旭ight	differences	 in	particu旭ar	 in	 type	
ゴA	 ｪIIEｫp	 Vicenza	 VWDp	 and	 severa旭	 type	 ゲ	 VWD	 patientssゴ葦 
Laboratories	which	use	one	of	the	new	generation	of	VWF	activ､
ity	assays	shou旭d	contemp旭ate	inc旭uding	a	second	activity	method	
during	 the	 initia旭	 diagnosis	 of	 VWDs	We	 propose	 an	 a旭gorithm	
for	the	inc旭usion	of	HズVWM	as	a	screening	too旭	in	the	diagnosis	





CLASSIFICATION VWFrAg VWF Ac Ratio IHVWM HズVWM LMWM IMWM HMWM MUTATION
Pズ Norma旭	VWF 72 ズゼ グsゼゾ QNORM RHWMW 30.8 ザズs葦 ザザs葦 UNK
Pゲグ Norma旭	VWF ゲゲズ 87 グsゼ葦 QNORM RHMWM ザゾsズ ザゲsジ ゴゾsゲ UNK
Pゲゲゾ Norma旭	VWF 102 82 0.80 QNORM RHWMW ザ芦sズ ザゾs葦 ゴゲsゾ psPゲザザゼL
Bゼ Norma旭	VWF ザグズ 277 グsゾゲ RHMWM QNORM ザグsゾ ザグsジ 38.7 UNK
Bゲゲ Norma旭	VWF ゲズジ 108 0.70 RHMWM QNORM ゴ芦sゾ ザジsゲ 37.0 UNK
P葦ジ 1 20 13 グs葦ズ QNORM RHMWM ザ葦sジ ザグsゾ 32.7 psCゲゲザグF
P葦ズ 1 20 18 グsゾグ QNORM RHMWM ジゾsザ ゴズsジ ゴズsザ psCゲゲザグF
Pゼグ 1 21 ゲ葦 グsゼ葦 RHMWM QNORM ゴゼsゾ ザズsゴ ザ葦sゾ psPゲゴ葦葦Q｠ps
FゲズグゲS
Pゴグズ 1 ジズ ザズ 0.78 RHMWM RHMWM ジザsゴ ザ葦s葦 20.2 psPゲザザゼL
Pゴゲザ 1 葦ゴ ジグ グs葦ズ RHMWM RHMWM ジザsザ ザズs芦 ゴグsゾ psPゲザザゼL
Pゾジ ゴA 20 11 グsズズ RHMWM QNORM 27.1 ザズsジ ザゼsズ psRゲザゼジC
Pゾ葦 ゴA ゴジ 10 グsジゴ RHMWM QNORM 32.1 28.1 ザゾs芦 psRゲザゼジH
Pゲゲゲ ゴA 23 10 グsジザ RHMWM QNORM ジズs葦 ゲ葦sゲ 38.3 psRゲザゼジC
B芦 ゴA 27 ゲ葦 グsズゾ RHMWM QNORM ゴ葦sゼ 33.0 ジグsザ UNK
Bゾ ゴA 21 8 0.38 RHMWM QNORM ザグsゾ ザザsジ ザズsゼ UNK
Pゲゴゲ ゴM 31 13 グsジゴ QNORM RHMWM ズグs葦 ゴジs芦 ゴジs葦 UNK
Pゲゴジ ゴM ザゾ ゲゾ グsジゾ QNORM RHMWM ズジsゲ ゴズsゼ 20.2 No mutation in 
exon	ゴ芦
Pゲゴズ ゴM ゴジ 葦 グsゴズ QNORM RHMWM ジズsゲ ゴゲsズ ザザsジ psRゲザゼジC
Pゴゲジ ゴM ゴズ 11 グsジジ QNORM RHMWM ズゾsゾ 18 22.1 psDゲゴゼゼEｧ
Lゲゴゼ芦de旭insE
Pゴゲ葦 ゴM ゴズ 葦 グsゴジ QNORM RHMWM 葦ゼsゼ 11.1 21.1 psRゲザゲズC
Pゴズゲ ゴM ゴズ ジ グsゲ葦 QNORM RHMWM 葦グs葦 13 ゴ葦sジ psRゲザゼジC
Pゲジ芦 2N 80 78 グsゾ芦 QNORM RHMWM ザグsジ ザゼsゾ 31.7 psQゲグズザH	
homozygous
Patient	 identifierp	c旭assification	based	on	the	 in､house	VW	mu旭timer	 ｪIHVWMｫ	resu旭tp	VWFp	mu旭timerp	densitometry	resu旭tsp	and	genetic	mutations	
shown	 if	 knowns	Mu旭timer	 resu旭ts	 were	 either	 quantitative旭y	 norma旭p	 QNORM	 or	 demonstrated	 a	 reduction	 of	 high	mo旭ecu旭ar	 weight	mu旭timers	
ｪRHMWMｫs	UNK	denotes	unknown	genetic	mutations




be	 further	 investigateds	 Subsequent	 studies	 wou旭d	 determine	
whether	a	higher	ratio	cut､	off	va旭ue	is	beneficia旭	in	the	diagnosis	
of	such	patientss





be旭ow	ゲグ	and	at	ズ	IU｠dL	 the	densitometry	was	difficu旭t	 to	 interprets	
At	decreasing	VWFrAg	the	proportion	of	LMWM	doub旭edp	with	a	cor､
responding	旭oss	of	IMWMp	a旭thoughp	the	percentage	of	HMWM	was	







IHVWM	 methods	 are	 旭aboriousp	 nonstandardizedp	 mu旭ti､	step	








can	 be	 used	 to	 reduce	 the	 work旭oad	 of	 traditiona旭	 mu旭timer	
methods	by	rapid旭y	screening	out	patients	with	norma旭	mu旭timer	
patterns	and	 is	performed	on	existing	 techno旭ogy	 is	 to	be	we旭､
comedp	especia旭旭y	by	旭ess	specia旭ized	旭aboratoriess	In	the	current	
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formatp	 using	 a	 sing旭e	 agarose	 concentration	 and	 without	 the	
sensitivity	 to	 visua旭ize	 the	mu旭timer	 trip旭et	 structurep	HズVWM	
is	un旭ike旭y	to	comp旭ete旭y	rep旭ace	in､	house	mu旭timer	ana旭ysis	but	
as	demonstrated	in	our	proposed	a旭gorithmp	it	wou旭d	be	a	usefu旭	
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Bleeding Assessment Score 
Physical examination  
Laboratory values  
(at least FVIII:C, VWF:Ag and VWF Ac)
VWF:Ag and/or VWF Ac < 30 IU/dL VWF:Ag and VWF Ac > 30 but < 50 IU/dL VWF:Ag and VWF Ac ≥50 IU/dL
one or more of the 
following features: 
-PFA ADP ↑ (not related to 
thrombocytopenia and/or 
reduced hematokrit and/or 
known platelet disorder) 
-Positive or new bleeding 
history (e.g. ISTH-BAT-Score 
> 4 points for men and 3 for 
female, resp.) 
- for aquired VWD possibly 
underlying condition (e.g. 
Aortic valve stenosis, MPS, 
paraproteinaemia, 
extracorporal assist device, 
etc.) 







Relative decrease of 
HMWM multimers 















FVIII:C < 55 
IU/dl , normal 
VWF
Further diagnostic depending on 
clinical features 
-Factor-VIII-binding assay  (type 2N VWD) 
-Bethesda assay (AHA) 
-Genetic analysis of the F8-gene 
RIPA
no 
VWF Ac < 30 IU/dL VWF Ac ≥30 IU/dL 
for confirmation
for diagnosing  
2B VWD
if applicable, 
repeat basic values 
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